In summary, SB attenuates the PI3K/AKT/mTOR pathway and diminishes cytokine release by competitively binding to ICOS on PBMCs of RA patients, offering potential enhancements to UC‐MSCs therapeutic outcomes. The gene discussed is AKT1; the disease is rheumatoid arthritis.